$0.88 -$0.01 (-1.1%)

12:46 PM EDT on 09/20/19

Cti Biopharma Corp (NASDAQ:CTIC)

CAPS Rating: 2 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Current Price $0.88 Mkt Cap $58.6M
Open $0.88 P/E Ratio 0.00
Prev. Close $0.89 Div. (Yield) $0.00 (0.0%)
Daily Range $0.86 - $0.89 Volume 47,741
52-Wk Range $0.63 - $1.48 Avg. Daily Vol.

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

236 Outperform
43 Underperform
 

All-Star Players

11 Outperform
10 Underperform
 

Wall Street

2 Outperform
2 Underperform
 

Top NASDAQ:CTIC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

afrisque61 (< 20)
Submitted February 15, 2015

Once a high-flyer, potentially poised for growth due to new product development.

kanstockman (< 20)
Submitted June 11, 2007

2008 a drug in Phase III stage II should be on the market with a half a billion in sales by the 2nd Q. Right now the stock is being dragged down by the sector componants.

NASDAQ:CTIC VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CTIC.

Recs

0
Member Avatar zzlangerhans (99.83) Submitted: 2/22/2016 11:17:03 AM : Underperform Start Price: $5.07 NASDAQ:CTIC Score: +138.58

I have to admit I got sucked into Cell Therapeutics' transient success with pacritinib and green thumbed them about a year ago, ruining my perfect record on the stock. Fortunately I never followed up that green thumb with a real money bet. As it turned out, pacritinib is going down the toilet along with all of Cell Therapeutics' other programs over the years. A red thumb is still the right bet for this stock no matter how much it looks like they've finally developed a legitimate drug.

This month the company withdrew their NDA for pacritinib thanks to an FDA full clinical hold regarding a detrimental effect of pacritinib on overall survival in both of the two phase III trials. That's a polite way of saying the drug kills people. Not good. Given how bad this looks and Cell Therapeutics' long history of failure, I think we can discard pacritinib from the company's value equation.

What's left? The new lead drug is tosedostat. In December management reported a complete response rate of 49% at an interim analysis of the phase II IST of tosedostat in AML. Tosedostat is also being tested for AML in a "Pick-A-Winner" program developed by the NCRI of the UK. Management is planning discussions regarding registrational trials of tosedostat with regulators in the US and UK later this year. Paclitaxel analogue Opaxio wasn't mentioned in the last earnings PR, although a phase III trial as maintenance therapy in ovarian cancer is supposedly in progress. Pixuvri is showing weak and static revenues, barely over 1M in the last quarter reported. This drug seems to be going nowhere commercially.

Cell Therapeutics has 128M in cash thanks to a series of vulture financings conducted in late 2015. These financings involved the creation of preferred stock equivalent to 90M of common, so there is at least 60M of hidden market cap in addition to the 190M cap based on the outstanding common. There's probably plenty of other preferred stock and options still out there that I haven't kept track of adding to the hidden cap. There's also 52M in long-term debt and a quarterly burn over 20M.

For some reason Cell Therapeutics isn't trading under cash despite the fact that several bios with better pedigrees and prospects are doing exactly that. If we subtract the debt and two quarters of burn from the cash that leaves us with 36M net as of the end of March 2016. Meanwhile, the market cap including preferred stock is over 250M with no positive catalysts apparent on the near term horizon. Cell Therapeutics may be catching a little air for now, but the street has proven to be a harsh mistress for biotech of late. I really don't see this ending well.

Recs

0
Member Avatar 78taxs (37.91) Submitted: 5/28/2015 2:00:01 PM : Outperform Start Price: $18.60 NASDAQ:CTIC Score: -136.78

Cancer. With less rad.

Recs

1
Member Avatar afrisque61 (< 20) Submitted: 2/15/2015 4:33:38 PM : Outperform Start Price: $22.10 NASDAQ:CTIC Score: -139.34

Once a high-flyer, potentially poised for growth due to new product development.

Leaderboard

Find the members with the highest scoring picks in CTIC.

Score Leader

IdahoInvestor

IdahoInvestor (35.30) Score: +365.52

The Score Leader is the player with the highest score across all their picks in CTIC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
ed11b < 20 6/26/2009 Underperform 5Y $503.97 -99.82% +229.11% +328.94 0 Comment
AlansMagicStick 42.37 6/29/2009 Underperform 5Y $504.06 -99.82% +227.35% +327.18 0 Comment
f19 < 20 6/4/2009 Underperform 3M $555.00 -99.84% +222.66% +322.50 1 Comment
RoxanneAdams 32.42 6/3/2009 Underperform 5Y $582.00 -99.85% +222.52% +322.37 0 Comment
mcornice 88.95 6/2/2009 Underperform 3M $603.00 -99.85% +221.29% +321.14 0 Comment
thestockstalker < 20 6/1/2009 Underperform NS $462.00 -99.81% +220.68% +320.49 0 Comment
TMFBiologyFool 66.04 8/3/2009 Underperform 1Y $453.00 -99.80% +202.14% +301.95 0 Comment
dcfoolz 71.42 8/28/2009 Underperform 5Y $477.00 -99.81% +189.35% +289.16 0 Comment
TMFNosediveflip 97.97 9/20/2006 Underperform 1Y $2,160.00 -99.96% +140.77% +240.73 0 Comment
cockeagledrvr 82.84 9/29/2006 Underperform 1Y $2,088.00 -99.96% +138.03% +237.99 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackLadenburg < 20 5/22/2014 Outperform NS $26.70 -96.68% +58.66% -155.35 0 Comment
trackthinkequity 89.08 10/15/2012 Outperform NS $15.80 -94.40% +109.57% -203.96 0 Comment
TrackPoisedTo < 20 9/13/2012 Underperform 5Y $34.50 -97.43% +107.91% +205.34 0 Comment
TrackUltraLong < 20 11/3/2011 Underperform NS $58.50 -98.49% +139.61% +238.10 1 Comment
TrackZacks < 20 10/27/2011 Outperform 3M $64.50 -13.18% -0.72% -12.46 1/4/2012 @ $56.00 1 Comment
TrackZacks < 20 8/19/2011 Underperform 3M $60.00 -1.67% +4.83% +6.50 8/24/2011 @ $59.00 1 Comment
TrackZacks < 20 4/4/2011 Underperform 3M $122.04 -13.94% +2.22% +16.16 5/2/2011 @ $105.03 1 Comment
TrackZacks < 20 12/7/2010 Underperform 3M $114.00 -11.08% +9.30% +20.38 2/17/2011 @ $101.37 1 Comment
TrackZacks < 20 9/14/2010 Underperform 3M $111.00 +4.05% +8.94% +4.89 11/5/2010 @ $115.50 1 Comment
TrackZacks < 20 1/16/2008 Outperform 3M $450.00 -62.67% -2.45% -60.22 3/18/2008 @ $168.00 1 Comment
TrackRodmanRen < 20 1/8/2007 Outperform NS $2,088.00 -91.32% -17.26% -74.06 3/23/2010 @ $181.20 0 Comment